Now Available: Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023
GlobalData has released its new PharmaPoint Drug Evaluation report, "Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023". HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line metastatic.
View full press release